Melanoma
News
FDA approves pembrolizumab for completely resected melanoma
Approval was based on improved recurrence-free survival in a randomized, double-blind, placebo-controlled, trial of 1,019 patients with completely...
From the Journals
Checkpoint inhibitors ‘viable treatment option’ in HIV-infected individuals
There were no concerning immune-mediated toxicities or changes in HIV-related parameters observed among 73 patients with HIV infection who had...
From the Journals
Poor-prognosis cancers linked to highest suicide risk in first year
Pancreatic and lung cancer patients had high rates of suicide in comparison to the general population, while breast and prostate cancer patients...
Latest News
Pembrolizumab approved for Merkel cell carcinoma
The FDA granted accelerated approval for the drug based on promising results in nonrandomized, open-label trial.
From the Journals
More data link severe sleep apnea and aggressive melanoma
The findings offer further evidence of the link between cancer and sleep-disordered breathing.
From the Journals
RCC strongly linked to melanoma, and vice versa
Clinicians need to be vigilant for RCCs in melanoma patients, and for melanomas in RCC patients.
Commentary
Strategies to Reduce Youth Indoor Tanning Injuries
Targeted campaigns have been largely unsuccessful in discouraging minors from tanning. New approaches to combating adolescent tanning injuries may...
From the Journals
Second-melanoma risk higher with indoor tanning
Tanning-bed users also had less time before the diagnosis of their second tumor.
Latest News
New pregnancy, genetic testing guidance added to AAD’s melanoma guidelines
Not every patient with cutaneous melanoma will need genetic testing, say the updated guidelines.
Conference Coverage
Nivo + ipi shows durable activity against metastatic melanoma
MUNICH – Four-year data from the Checkmate 067 study bolster earlier findings supporting the checkpoint inhibitor combination in first line...
From the Journals
Checkpoint inhibitor doubles 3-year survival rate of BRAF wild-type advanced melanoma
The 3-year overall survival rate for patients treated with nivolumab was 51.2%, compared with 21.6% for those who received dacarbazine.